drugset / Trial / NCT04973982
ENvarsus for Impaired Glucose Tolerance Post REnal transplAnT
Withdrawn
Barts & The London NHS Trust
RandomizedParallel-groupOpen-labelTreatment
Summary
Our hypothesis is that switching from the current standard of care twice daily Adoport (Tacrolimus) to once daily Envarsus (tacrolimus) in patients who have impaired glucose tolerance post-transplant will lead to an improvement in their glucose tolerance, and may reduce the subsequent incidence of PTDM.
Timeline
- Start
- 2022-01-31
- Primary completion
- 2022-08-01
- Completion
- 2022-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tacrolimus | Small molecule | — | Oral |
Indications
No indication recorded.